Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells

Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically

(2012) Michal Zapotocky et al.   CANCER LETTERS

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

(2010) A Quintás-Cardama et al.   LEUKEMIA

Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide

(2010) N Hajji et al.   ONCOGENE

Histone deacetylases and epigenetic therapies of hematological malignancies

(2010) Ciro Mercurio et al.   PHARMACOLOGICAL RESEARCH

HDAC inhibitor-based therapies and haematological malignancy

(2009) L. Stimson et al.   ANNALS OF ONCOLOGY

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Modifications of RNA polymerase II are pivotal in regulating gene expression states

(2009) Emily Brookes et al.   EMBO REPORTS

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone H3 Lysine 56 Acetylation Is Linked to the Core Transcriptional Network in Human Embryonic Stem Cells

(2009) Wei Xie et al.   MOLECULAR CELL

30 nm Chromatin Fibre Decompaction Requires both H4-K16 Acetylation and Linker Histone Eviction

(2008) Philip J.J. Robinson et al.   JOURNAL OF MOLECULAR BIOLOGY